Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 10, 2014, Pages 6525-6534

  Poor, Stephen H ^a   Qiu, Yubin ^a   Fassbender, Elizabeth S ^a   Shen, Siyuan ^a   Woolfenden, Amber ^a   Delpero, Andrea ^a   Kim, Yong ^a   Buchanan, Natasha ^a   Gebuhr, Thomas C ^a   Hanks, Shawn M ^a   Meredith, Erik L ^a   Jaffee, Bruce D ^a   Dryja, Thaddeus P ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Choroidal neovascularization; Laser; Mice; VEGF

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; DEXAMETHASONE; PAZOPANIB; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; MESSENGER RNA; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE INACTIVATION; GENOTYPE; IC50; INFLAMMATORY DISEASE; LASER COAGULATION; MICROSCOPY; NONHUMAN; PIGMENT EPITHELIUM; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RETROSPECTIVE STUDY; RNA SEQUENCE; SCLEROTOMY; SUBRETINAL NEOVASCULARIZATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHOROIDAL NEOVASCULARIZATION; COMPARATIVE STUDY; DISEASE MODEL; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; GENETICS; MALE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; LASER COAGULATION; MALE; MICE; MICE, INBRED C57BL; REPRODUCIBILITY OF RESULTS; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908110479     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15067     Document Type: Article

References (28)

1. Ishibashi T, Miller H, Orr G, Sorgente N, Ryan SJ. Morphologic observations on experimental subretinal neovascularization in the monkey. Invest Ophthalmol Vis Sci. 1987;28:1116–1130.
2. Nehemy MB, Torqueti-Costa L, Magalhaes EP, Vasconcelos- Santos DV, Vasconcelos AJ. Choroidal neovascularization after accidental macular damage by laser. Clin Experiment Ophthalmol. 2005;33:298–300.
3. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338–346.
4. Bora PS, Sohn J-H, Cruz JMC, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005;174:491–497.
5. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and targetindependent angiogenesis suppression by siRNA via TLR 3. Nature. 2008;452:591–597.
6. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 2006;103:2328–2333.
7. Bora NS, Kaliappan S, Jha P, et al. Complement activation via alternative pathway is critical in the development of laserinduced choroidal neovascularization: role of factor B and factor H. J Immunol. 2006;177:1872–1878.
8. March DR, Proctor LM, Stoermer MJ, et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol. 2004;65:868–879.
9. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-(2,3- dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]- 2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008;51:4632–4640.
10. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178–2189.
11. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008;173:265–277.
12. Meingassner JG, Fahrngruber H, Kowalsky E, et al. NVPBFH772, a potent inhibitor of VEGF receptor tyrosine kinases, is effective in models of skin inflammation. In: Annual Meeting of the Society for Investigative Dermatology; May 4 to 7, 2011. Phoenix, AZ. Abstract 480.
13. Amparo F, Sadrai Z, Jin Y, et al. Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization. Invest Ophthalmol Vis Sci. 2013;54:537–544.
14. McLaughlin MM, Paglione MG, Slakter J, et al. Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration. JAMA Ophthalmol. 2013;131:1595–1601.
15. Subramanian H, Kashem SW, Collington SJ, Qu H, Lambris JD, Ali H. PMX-53 as a dual CD88 antagonist and an agonist for mas-related gene 2 (MrgX2) in human mast cells. Mol Pharmacol. 2011;79:1005–1013.
16. Zhu Y, Lu Q, Shen J, et al. Improvement and optimization of standards for a preclinical animal test model of laser induced choroidal neovascularization. PLos ONE 2014;9:e94743.
17. Lambert V, Lecomte J, Hansen S, et al. Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat Protoc. 2013;8:2197–2211.
18. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187–191.
19. Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD. Deletion of nicotinamide nucleotide transhydrogenase. A new quantitative trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes. 2006;55:2153–2156.
20. Mattapallil MJ, Wawrousek EF, Chan C-C, et al. The rd8 mutation of the crb1 gene is present in vendor lines of C57BL/ 6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci. 2012; 53:2921–2927.
21. Takahashi K, Saishin Y, Saishin Y, King AG, Rl, Levin, Campochiaro PA. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 2009;127:494–499.
22. Consortium, AMD Gene, Fritsche LG, Chen W, et al. Seven new loci associated with age-related macular degeneration. Nature Genet. 2013;45:433–439.
23. Baas DC, Ho L, Ennis S, et al. The complement component 5 gene and age-related macular degeneration. Ophthalmology. 2010;117:500–511.
24. Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 and associated with high risk of advanced age-related macular degeneration. Nat Genet. 2013;45:1366–1370.
25. Nishiguchi KM, Yasuma TR, Tomida D, et al. C9-R95X polymorphism in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53: 508–512.
26. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010; 29:95–112.
27. Khandhadia S, Cipriani V, Yates JRW, Lotery AJ. Age-related macular degeneration and the complement system. Immunobiology. 2012;217:127–146.
28. Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age-related macular degeneration in the EUREYE study. Ophthalmology. 2007;114:1157–1163.